spectrum pharmaceuticals  irvine technology center   visitors foursquarelog insign upnearbyget inspiredtop pickstrendingfoodcoffeenightlifefunshoppingplanning a trip to los angelesfoursquare can help you find the best places to go tofind great things to dospectrum pharmaceuticalsofficeirvine technology center irvinesavesharetipsspectrum pharmaceuticalsno tips and reviewslog in to leave a tip herepostno tips yetwrite a short note about what you liked what to order or other helpful advice for visitors photorelated searchesspectrum pharmaceuticals irvine  spectrum pharmaceuticals irvine photos  spectrum pharmaceuticals irvine location  spectrum pharmaceuticals irvine address  spectrum pharmaceuticals irvine  spectrum pharmaceuticals irvine  spectrum pharmaceuticals irvine technology center irvineaboutblogbusinessescitiesdevelopershelpjobscookies updatedprivacy updatedtermsenglishenglish français deutsch bahasa indonesia italiano  한국어 português русский español ภาษาไทย türkçe citiesatlantaaustinbostonchicagodallasdenverhoustonlas vegaslos angelesnew yorkphiladelphiaportlandsan diegosan franciscoseattlewashington dccountriesbelgiumbrazilcanadachilefinlandfrancegermanygreat britainhungaryindonesiajapanmexiconetherlandsphilippinesrussiasingaporespainthailandturkeymore great places in irvineabcdefghijklmnopqrstuvwxyzfoursquare    lovingly made in nyc  sfspectrum pharmaceuticals technology dr barrancairvine ca united statesget directions see moreunited states » orange county » irvine » irvine technology centerprofessional  other places » officeis this your business claim it nowmake sure your information is up to date plus use our free tools to find new customersyou must enable javascript to use foursquarecomwe use the latest and greatest technology available to provide the best possible web experienceplease enable javascript in your browser settings to continuedownload foursquare for your smart phone and start exploring the world around you biopharmaceuticals market research reports under pharmaceuticals at rnr market research advanced search     salesrnrmarketresearchcom search market research reports market research assistance salesrnrmarketresearchcomon the web refine resultby datelast monthlast  monthslast  monthslast yearlast  years by price  home     life sciences    pharmaceuticals    biopharmaceuticals biopharmaceuticals market research reports globally the biopharmaceuticals market is expected to drive the double digit growth rate the biopharma segment is more costly than traditional medications which needs higher investments and longer development times the biopharmaceuticals segment addreses several therapeutic areas such as neurology infectious diseases cardiovascular oncology etc biopharmaceuticals is categorised into the recombinant proteins insulin erythropoietins interferons colony stimulating factors immunoglobulins recombinant blood factors growth hormones recombinant enzymes interleukins growth factors monoclonal antibodies and purified proteins the recombinant proteins lead the biopharmaceuticals market globally with highest percentage follwed by monoclonal antibodies the recombinant proteins market is considered to be down in developed countries due to biosimilar entry restrictions into the market and increase in cost containment measures the monoclonal antibodies market witness strong gview more globally the biopharmaceuticals market is expected to drive the double digit growth rate the biopharma segment is more costly than traditional medications which needs higher investments and longer development times the biopharmaceuticals segment addreses several therapeutic areas such as neurology infectious diseases cardiovascular oncology etc biopharmaceuticals is categorised into the recombinant proteins insulin erythropoietins interferons colony stimulating factors immunoglobulins recombinant blood factors growth hormones recombinant enzymes interleukins growth factors monoclonal antibodies and purified proteins the recombinant proteins lead the biopharmaceuticals market globally with highest percentage follwed by monoclonal antibodies the recombinant proteins market is considered to be down in developed countries due to biosimilar entry restrictions into the market and increase in cost containment measures the monoclonal antibodies market witness strong growth in developed and emerging economies due to rich late stage pipeline products the global biopharmaceutical market covers top eight regions us germany japan france italy spain uk and canada also the share is increased in emerging markets such as brazil russia india china mexico turkey and south korea the biggest restraint for this market is to get market approval for its products out of every ten drugs only three to four succeed to obtain concerned market approval and ones got the approval turned to be goldmines for investorsthe us is the biggest geographic market witness sharp decline due to spate of policy changes grants and the recent health care reform bill and aarc the industry drives due to its effectiveness and its ability to defend outside the reach of traditional small molecule drugs growth of biopharma in emerging markets approval of new products expansion of therapeutic drugs from existing products increase in biopharmaceutical research activity and participating in merger and acquisition activities including involvement in bioventures the biopharmaceutical market is directing towards licensing deals and allainces to get benefit to enter into the newer technologies of biopharmaceutical segment view less biopharmaceuticals market research reports titlepublishedprice global and chinese biopharmaceuticals industry  market research reportby prof research icals manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industryfirstly the report provides a basic overview of the industry including its definition applications and manufacturing tecjun bio industry markets in chinaby amid er consumption and capital investment for over two decades this new study examines chinas economic trends investment environment industry development supply and demand industry capacity industry structure marketing channels and major industrymay biotechnology products companies in chinaby amid and economy china is one of the worlds major producers for industrial and consumer products far outpacing other economies in the world china is the worlds fastest growing market for the consumptions of goods and services the chinese economy mamay biotechnology products industry industry forecasts  china focusby amid one of the worlds major producers for industrial and consumer products far outpacing other economies in the world china is the worlds fastest growing market for the consumptions of goods and services the chinese economy maintains a high speed grmay emea europe middle east and africa biochar market report by qyresearch group enue million usd market share and growth rate of biochar for these regions from  to  forecast  europe germany france uk russia italy and benelux  middle east saudi arabia israel uae and iran  africa soapr actelion partnering deals and alliances  to by current partnering th insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data the reapr alkermes partnering deals and alliances  to by current partnering th insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data the reapr amylin pharmaceuticals partnering deals and alliances  to by current partnering ides an indepth insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data apr astrazeneca partnering deals and alliances  to by current partnering depth insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data thapr biocon partnering deals and alliances  to by current partnering h insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of the most up to date deal and company data the repapr                 next » avail upto  discount on below publisher reports azoth analytics technavio spectrum pharmaceuticals inc our company our company our company company philosophy partnerships management board of directors careers product portfolio product portfolio commercial latestage rolontistm eflapegrastim qapzolatm apaziquone development poziotinib outlicensingglossary product returns investor relations investor relations press releases events and presentations corporate governance management board of directors committee composition insider transactions annual report and proxy information financial information sec filings k annual reports quarterly results financial statements stock information historic stock lookup investment calculator stocksplit history analyst coverage ownership profile investor faqs patient assistance medical professionals medical professionals clinical trials grants investigator initiated trials expanded access program careers contact us home  our company about spectrum pharmaceuticals spectrum pharmaceuticals is a commercialstage biotechnology company with fully integrated commercial and drug development operations and a leader in hematologyoncology our primary strategy is comprised of acquiring developing and commercializing a broad and diverse pipeline of latestage clinical and commercial products in addition to an efficient inhouse clinical development organization with regulatory and data management capabilities spectrum has established a commercial infrastructure for its marketed products currently we have six oncologyhematology products on the market that target different types of nonhodgkins lymphoma advanced metastatic colorectal cancer a type of acute lymphoblastic leukemia all and multiple myeloma careers at spectrum visit our careers page to learn about new job opportunities and how to become a part of the spectrum team spectrum also has two drugs in latestage development rolontistm eflapegrastim being developed for chemotherapyinduced neutropenia in patients with breast cancer qapzola apaziquone for intravesical instillation being developed for immediate intravesical instillation posttransurethral resection of bladder tumors in patients with nonmuscle invasive bladder cancer our passion to identify develop and deliver important options for patients suffering from cancer is behind every action we take at spectrum we are committed to excellence and strive to make a difference in the lives of patients every day the key is our people collectively the members of our team have relevant experience in both the development and marketing of oncology drugs and the growth of profitable business ventures our goal is to bring quality drugs to patients spectrum pharmaceuticals actively seeks and evaluates potentially important drug candidates once we identify these candidates we rapidly assess preclinical and clinical data and the commercialization potential of candidates then through both inlicensing and codevelopment partnerships we provide the expertise and neccesary funding to bring the most promising products through the complex development process to market in order to maximize the commercial potential of our current and future drugs spectrum has assembled a distinguished commercial team that was recruited from the top sales performers in the oncology specialty arena and who are dedicated to bringing important quality treatments to cancer patients spectrums code of conduct at spectrum we will use all lawful and ethical means possible to bring our therapy options to the right patients in the right way we will be personally responsible to understand and adhere to the letter and spirit of all laws and company policies that pertain to our daily business we will partner only with healthcare professionals suppliers and other business partners who share our commitment to understand and uphold the laws and regulations that apply to our operations we will respect and protect the dignity and privacy of patients healthcare professionals and their staff business partners competitors and our fellow employees we will promptly and cooperatively report without fear of retaliation any behavior contrary to these principles to management the compliance officer or the compliance and whistleblower hotline you may contact spectrums compliance officer at any time at compliancesppirxcom click here to view a pdf of spectrums notice of compliance click here to view a pdf of spectrums compliance program back to top our company company philosophy partnerships management board of directors careers product portfolio commercial latestagedevelopment glossary product returns investor relations press releases events and presentations corporate governance annual report and proxy information financial information stock information investor faqs patient assistance star medical professionals clinical trials medical affairs grants investigator initiated trials careers contact us this web site contains forwardlooking statements within the meaning of section a of the securities act of  as amended and section e of the securities exchange act of  as amended and in reliance upon the safe harbor provisions of the private securities litigation reform act of  such forwardlooking statements are based on the beliefs of the companys management as well as assumptions made by and information currently available to the companys management readers should not put undue reliance on these forwardlooking statements forwardlooking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified spectrum pharmaceuticals incs actual results may differ materially from the results projected in the forwardlooking statements factors that might cause such a difference include but are not limited to those discussed in the companys most recent form k and qs we do not plan to update any such forwardlooking statements and expressly disclaim any duty to update the information contained in this filing except as required by law all contents copyright spectrum pharmaceuticals inc   all rights reserved ppall site map  privacy policy  terms of use  linking policycontact us  webmail spectrum pharmaceuticals inc  events  presentations our company our company company philosophy partnerships management board of directors careers product portfolio product portfolio commercial latestage rolontistm eflapegrastim qapzolatm apaziquone development poziotinib outlicensing glossary product returns evomela product returns folotyn product returns marqibo water bath kit destruction verification form marqibo equipment decontamination verification and shipment preparation marqibo instruction for sites to return usedunused material to almac clinical services fusilev  beleodaq product returns zevalin product returns investor relations investor relations press releases events and presentations corporate governance management board of directors committee composition insider transactions annual report and proxy information financial information sec filings k annual reports quarterly results financial statements stock information historic stock lookup investment calculator stocksplit history analyst coverage ownership profile investor faqs litigation documents patient assistance medical professionals medical professionals clinical trials grants investigator initiated trials careers contact us home  investor relations  events  presentations events  presentations upcoming event aug    pm et spectrum pharmaceuticals q  earnings call listen to webcast remind me please sign up for email alert notification archived events jun    pm et jefferies  global healthcare conference listen to webcast may    pm pt bank of america merrill lynch  healthcare conference listen to webcast may    am et deutsche bank nd annual health care conference listen to webcast may    pm et spectrum pharmaceuticals q  earnings call listen to webcast mar    pm et spectrum pharmaceuticals q  earnings call listen to webcast feb    am et rbc capital markets  healthcare conference listen to webcast aug    pm et spectrum pharmaceuticals q  earnings call listen to webcast may    pm et spectrum pharmaceuticals q  earnings call listen to webcast mar    pm pt fourth quarter  financial results conference call listen to webcast nov    pm pt third quarter  financial results conference call listen to webcast aug    pm pt second quarter  financial results conference call listen to webcast  add file to briefcase back to top nasdaq sppi price  change   day high  day low  volume   pm et on jul   delayed at least  minutesprovided by esignal shareholder tools search ir our company company philosophy partnerships management board of directors careers product portfolio commercial latestagedevelopment outlicensing glossary investor relations press releases events and presentations corporate governance annual report and proxy information financial information stock information investor faqs litigation documents patient assistance star medical professionals clinical trials medical affairs grants investigator initiated trials careers contact us this web site contains forwardlooking statements within the meaning of section a of the securities act of  as amended and section e of the securities exchange act of  as amended and in reliance upon the safe harbor provisions of the private securities litigation reform act of  such forwardlooking statements are based on the beliefs of the companys management as well as assumptions made by and information currently available to the companys management readers should not put undue reliance on these forwardlooking statements forwardlooking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified spectrum pharmaceuticals incs actual results may differ materially from the results projected in the forwardlooking statements factors that might cause such a difference include but are not limited to those discussed in the companys most recent form k and qs we do not plan to update any such forwardlooking statements and expressly disclaim any duty to update the information contained in this filing except as required by law all contents copyright spectrum pharmaceuticals inc   all rights reserved ppall site map  privacy policy  terms of use  linking policy  contact us remote support  clinical support  webmail microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft spectrum pharmaceuticals inc product portfolio our company our company company philosophy partnerships management board of directors careers product portfolio product portfolio commercial latestage rolontistm eflapegrastim qapzolatm apaziquone development poziotinib outlicensingglossary product returns investor relations investor relations press releases events and presentations corporate governance management board of directors committee composition insider transactions annual report and proxy information financial information sec filings k annual reports quarterly results financial statements stock information historic stock lookup investment calculator stocksplit history analyst coverage ownership profile investor faqs patient assistance medical professionals medical professionals clinical trials grants investigator initiated trials expanded access program careers contact us home  product portfolio products spectrum and its subsidiaries have six fdaapproved oncologyhematology products and two products in latestage development the company also has as a diversified portfolio of proprietary drugs including a number that address large markets which could be transformative to the company these products are in various stages of development with a focus on oncologyhematology click any area on the chart below to learn more on a specific drug a back to top our company company philosophy partnerships management board of directors careers product portfolio commercial latestagedevelopment glossary product returns investor relations press releases events and presentations corporate governance annual report and proxy information financial information stock information investor faqs patient assistance star medical professionals clinical trials medical affairs grants investigator initiated trials careers contact us this web site contains forwardlooking statements within the meaning of section a of the securities act of  as amended and section e of the securities exchange act of  as amended and in reliance upon the safe harbor provisions of the private securities litigation reform act of  such forwardlooking statements are based on the beliefs of the companys management as well as assumptions made by and information currently available to the companys management readers should not put undue reliance on these forwardlooking statements forwardlooking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified spectrum pharmaceuticals incs actual results may differ materially from the results projected in the forwardlooking statements factors that might cause such a difference include but are not limited to those discussed in the companys most recent form k and qs we do not plan to update any such forwardlooking statements and expressly disclaim any duty to update the information contained in this filing except as required by law all contents copyright spectrum pharmaceuticals inc   all rights reserved ppall site map  privacy policy  terms of use  linking policycontact us  webmail spectrum pharmaceuticals inc product portfolio our company our company company philosophy partnerships management board of directors careers product portfolio product portfolio commercial latestage rolontistm eflapegrastim qapzolatm apaziquone development poziotinib outlicensingglossary product returns investor relations investor relations press releases events and presentations corporate governance management board of directors committee composition insider transactions annual report and proxy information financial information sec filings k annual reports quarterly results financial statements stock information historic stock lookup investment calculator stocksplit history analyst coverage ownership profile investor faqs patient assistance medical professionals medical professionals clinical trials grants investigator initiated trials expanded access program careers contact us home  product portfolio products spectrum and its subsidiaries have six fdaapproved oncologyhematology products and two products in latestage development the company also has as a diversified portfolio of proprietary drugs including a number that address large markets which could be transformative to the company these products are in various stages of development with a focus on oncologyhematology click any area on the chart below to learn more on a specific drug a back to top our company company philosophy partnerships management board of directors careers product portfolio commercial latestagedevelopment glossary product returns investor relations press releases events and presentations corporate governance annual report and proxy information financial information stock information investor faqs patient assistance star medical professionals clinical trials medical affairs grants investigator initiated trials careers contact us this web site contains forwardlooking statements within the meaning of section a of the securities act of  as amended and section e of the securities exchange act of  as amended and in reliance upon the safe harbor provisions of the private securities litigation reform act of  such forwardlooking statements are based on the beliefs of the companys management as well as assumptions made by and information currently available to the companys management readers should not put undue reliance on these forwardlooking statements forwardlooking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified spectrum pharmaceuticals incs actual results may differ materially from the results projected in the forwardlooking statements factors that might cause such a difference include but are not limited to those discussed in the companys most recent form k and qs we do not plan to update any such forwardlooking statements and expressly disclaim any duty to update the information contained in this filing except as required by law all contents copyright spectrum pharmaceuticals inc   all rights reserved ppall site map  privacy policy  terms of use  linking policycontact us  webmail market report spectrum pharmaceuticals inc  product pipeline review   about us • publishers • contact us • cart login  register all industries business  finance  business  financial services  insurance  marketing consumer  food  beverages  consumer goods  food  retailing healthcare  biotechnology  healthcare  medical devices  pharmaceuticals heavy industry  construction  energy  manufacturing  materials  transportation internet  media  ebusiness  internet  media  publishing public sector  defense  education  government telecom  computing  computer technology  fixed networks  software  wireless companycountry reports  company reports  country reports  regional reports   processing spectrum pharmaceuticals inc  product pipeline review   apr    global markets direct   pages  usd  click here to open the popup youve added the following report to your cartclose cart summary total items subtotal      report summary table of contents companies request details related global markets directs spectrum pharmaceuticals inc  product pipeline review   provides an overview of the spectrum pharmaceuticals incs pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of spectrum pharmaceuticals incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescopethe report provides brief overview of spectrum pharmaceuticals inc including business description key information and facts and its locations and subsidiariesthe report reviews current pipeline of spectrum pharmaceuticals incs human therapeutic division and enlists all their major and minor projectsthe report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestonesspecial feature on outlicensed and partnered product portfoliothe report summarizes all the dormant and discontinued pipeline projectslatest company statementlatest news and deals relating to the spectrum pharmaceuticals incs pipeline productsreasons to buyevaluate spectrum pharmaceuticals incs strategic position with total access to detailed information on its product pipelineassess the growth potential of spectrum pharmaceuticals inc in its therapy areas of focusidentify new drug targets and therapeutic classes in the spectrum pharmaceuticals incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areasexploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gapsdevelop strategic initiatives by understanding the focus areas of spectrum pharmaceuticals inc and exploit collaboration and partnership opportunitiesidentify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantageplan mergers and acquisitions effectively by identifying the most promising pipeline of spectrum pharmaceuticals incdevelop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scopeexplore the dormant and discontinued projects of spectrum pharmaceuticals inc and identify potential opportunities in those areasavoid intellectual property rights related issues table of contentstable of contentslist of tableslist of figuresspectrum pharmaceuticals inc snapshotspectrum pharmaceuticals inc overviewkey informationkey factsspectrum pharmaceuticals inc  research and development overviewkey therapeutic areasspectrum pharmaceuticals inc  pipeline reviewpipeline products by stage of developmentpipeline products  monotherapypipeline products  partnered productspartnered productscombination treatment modalitiesspectrum pharmaceuticals inc  pipeline products glancespectrum pharmaceuticals inc  late stage pipeline productspreregistration productscombination treatment modalitiesphase iii productscombination treatment modalitiesspectrum pharmaceuticals inc  clinical stage pipeline productsphase ii productscombination treatment modalitiesphase i productscombination treatment modalitiesspectrum pharmaceuticals inc  early stage pipeline productspreclinical productscombination treatment modalitiesspectrum pharmaceuticals inc  unknown stage pipeline productsunknown productscombination treatment modalitiesspectrum pharmaceuticals inc  drug profilesmelphalanproduct descriptionmechanism of actionrd progressapaziquoneproduct descriptionmechanism of actionrd progresspralatrexateproduct descriptionmechanism of actionrd progressvincristine sulfateproduct descriptionmechanism of actionrd progressyttritum  ibritumomab tiuxetanproduct descriptionmechanism of actionrd progressbelinostatproduct descriptionmechanism of actionrd progresslucanthone hydrochlorideproduct descriptionmechanism of actionrd progressmenadioneproduct descriptionmechanism of actionrd progressortataxelproduct descriptionmechanism of actionrd progressozarelixproduct descriptionmechanism of actionrd progressspiproduct descriptionmechanism of actionrd progressspiproduct descriptionmechanism of actionrd progressmtrnproduct descriptionmechanism of actionrd progressspiproduct descriptionmechanism of actionrd progresstopotecan hydrochloride liposomalproduct descriptionmechanism of actionrd progressvinorelbine tartrate liposomalproduct descriptionmechanism of actionrd progressrituximab biosimilarproduct descriptionmechanism of actionrd progressspectrum pharmaceuticals inc  pipeline analysisspectrum pharmaceuticals inc  pipeline products by targetspectrum pharmaceuticals inc  pipeline products by route of administrationspectrum pharmaceuticals inc  pipeline products by molecule typespectrum pharmaceuticals inc  pipeline products by mechanism of actionspectrum pharmaceuticals inc  recent pipeline updatesspectrum pharmaceuticals inc  dormant projectsspectrum pharmaceuticals inc  discontinued pipeline productsdiscontinued pipeline product profilesefaproxiralortataxelrhspectrum pharmaceuticals inc  company statementspectrum pharmaceuticals inc  locations and subsidiarieshead officeother locations  subsidiariesappendixmethodologycoveragesecondary researchprimary researchexpert panel validationcontact usdisclaimerlist of tablesspectrum pharmaceuticals inc key informationspectrum pharmaceuticals inc key factsspectrum pharmaceuticals inc  pipeline by indication spectrum pharmaceuticals inc  pipeline by stage of development spectrum pharmaceuticals inc  monotherapy products in pipeline spectrum pharmaceuticals inc  partnered products in pipeline spectrum pharmaceuticals inc  partnered products combination treatment modalities spectrum pharmaceuticals inc  preregistration spectrum pharmaceuticals inc  phase iii spectrum pharmaceuticals inc  phase ii spectrum pharmaceuticals inc  phase i spectrum pharmaceuticals inc  preclinical spectrum pharmaceuticals inc  unknown spectrum pharmaceuticals inc  pipeline by target spectrum pharmaceuticals inc  pipeline by route of administration spectrum pharmaceuticals inc  pipeline by molecule type spectrum pharmaceuticals inc  pipeline products by mechanism of action spectrum pharmaceuticals inc  recent pipeline updates spectrum pharmaceuticals inc  dormant developmental projectsspectrum pharmaceuticals inc  discontinued pipeline products spectrum pharmaceuticals inc other locationsspectrum pharmaceuticals inc subsidiarieslist of figuresspectrum pharmaceuticals inc  pipeline by top  indication spectrum pharmaceuticals inc  pipeline by stage of development spectrum pharmaceuticals inc  monotherapy products in pipeline spectrum pharmaceuticals inc  partnered products in pipeline spectrum pharmaceuticals inc  pipeline by top  target spectrum pharmaceuticals inc  pipeline by top  route of administration spectrum pharmaceuticals inc  pipeline by top  molecule type spectrum pharmaceuticals inc  pipeline products by top  mechanism of action  companies mentioned in this reportspectrum pharmaceuticals inc this report does not have a press release associated with it order today format pdf  usd license single user delivery by email   business day the fast market research advantage only the best all of our research is sourced from the most trusted and established global analysts and consultancies client focused from startups to multinationals we focus on providing the right research to our diverse client base shop securely our usbased customer service team and ecommerce systems adhere to the highest data security standards industryleading customer support individualized assistance from our expert staff is never more than an email or phone call away best price guarantee we are committed to providing the best research at the lowest cost we will match any published price for the same report guaranteed easy ordering once you’ve found the right report click ‘order now’ and complete the checkout process using any major credit card check or wirebank transferneed multiuser or enterprise license pricing contact us for a custom quote about the publisher global markets direct is a leading provider of global business intelligence and market analysis it publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industryspecific information publisher details privacy policy  terms of use  flashalerts copyright copy  fast market research inc spectrum pharmaceuticals inc a global commercialstage biotechnology company our company our company company philosophy partnerships management board of directors careers product portfolio product portfolio commercial latestage rolontistm eflapegrastim qapzolatm apaziquone development poziotinib outlicensing glossary product returns investor relations investor relations press releases events and presentations corporate governance management board of directors committee composition insider transactions annual report and proxy information financial information sec filings k annual reports quarterly results financial statements stock information historic stock lookup investment calculator stocksplit history analyst coverage ownership profile investor faqs patient assistance medical professionals medical professionals clinical trials grants investigator initiated trials expanded access program careers contact us our commitment to patients spectrums core mission is to bring pharmaceutical products to patients for unmet medical needs to this mission we bring our years of drug development expertise coupled with the insight of working in many different oncology indications learn more  our products spectrum and its subsidiaries have six marketed oncologyhematology products three for different types of nonhodgkins lymphoma one for advanced metastatic colorectal cancer one for a certain type of acute lymphoblastic leukemia all and one for multiple myeloma there are two products in latestage development as well as a broad and diversified portfolio of proprietary drugs in various stages of development all with a focus on oncology and hematology learn more  company highlights spectrum pharmaceuticals announces second quarter  financial results teleconference and webcastthursday july   spectrum pharmaceuticals highlights results of a combination study of folotynž pralatrexate injection plus romidepsin presented at the th international conference on malignant lymphoma icml meetingmonday june th  spectrum pharmaceuticals highlights three abstracts of clinical data at the  american society of clinical oncology asco annual meeting in chicago illinois june  friday june nd  expanding patient options our passion to deliver additional options for patients suffering from cancer is behind every action we take we will work to understand their needs and develop new and innovative therapies that offer hope for improved disease outcomes learn more about the spectrum philosophy our company company philosophy partnerships management board of directors careers product portfolio commercial latestagedevelopment glossary product returns investor relations press releases events and presentations corporate governance annual report and proxy information financial information stock information investor faqs patient assistance star medical professionals clinical trials medical affairs grants investigator initiated trials careers contact us this web site contains forwardlooking statements within the meaning of section a of the securities act of  as amended and section e of the securities exchange act of  as amended and in reliance upon the safe harbor provisions of the private securities litigation reform act of  such forwardlooking statements are based on the beliefs of the companys management as well as assumptions made by and information currently available to the companys management readers should not put undue reliance on these forwardlooking statements forwardlooking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified spectrum pharmaceuticals incs actual results may differ materially from the results projected in the forwardlooking statements factors that might cause such a difference include but are not limited to those discussed in the companys most recent form k and qs we do not plan to update any such forwardlooking statements and expressly disclaim any duty to update the information contained in this filing except as required by law all contents copyright spectrum pharmaceuticals inc š  all rights reserved ppall site map  privacy policy  terms of use  linking policy  contact us remote support  clinical support  webmail spectrum pharmaceuticals inc  contact us our company our company company philosophy partnerships management board of directors careers product portfolio product portfolio commercial latestage rolontistm eflapegrastim qapzolatm apaziquone development poziotinib outlicensing glossary product returns investor relations investor relations press releases events and presentations corporate governance management board of directors committee composition insider transactions annual report and proxy information financial information sec filings k annual reports quarterly results financial statements stock information historic stock lookup investment calculator stocksplit history analyst coverage ownership profile investor faqs patient information patient assistance star colorectal cancer nonhodgkins lymphoma acute lymphoblastic leukemia peripheral tcell lymphoma osteosarcoma medical professionals medical professionals clinical trials grants investigator initiated trials careers contact us home contact contact us please contact us by using our form below your name email address message click to follow us on compliance helpline if you would like to provide feedback to the compliance team or report any suspected or known misconduct please call the anonymous helpline below  product patents please click here to view information on spectrum pharmaceuticals product patents spectrum global offices global corporate office spectrum pharmaceuticals  s eastern avenue  henderson nv  phone   fax   research  development offices spectrum pharmaceuticals technology drive irvine ca  phone   fax   los angeles office spectrum pharmaceuticals oak crest drive suite  westlake village ca  phone   spectrum pharma canada  lachance sherbrooke quebec jj b canada phone   fax   spectrum oncology pvt ltd  free press house nariman point mumbai  india phone      fax      our company company philosophy partnerships management board of directors careers product portfolio commercial latestagedevelopment glossary product returns investor relations press releases events and presentations corporate governance annual report and proxy information financial information stock information investor faqs patient information patient assistance star colorectal cancer nonhodgkins lymphoma acute lymphoblastic leukemia peripheral tcell lymphoma osteosarcoma medical professionals clinical trials medical affairs grants investigator initiated trials careers contact us this web site contains forwardlooking statements within the meaning of section a of the securities act of  as amended and section e of the securities exchange act of  as amended and in reliance upon the safe harbor provisions of the private securities litigation reform act of  such forwardlooking statements are based on the beliefs of the companys management as well as assumptions made by and information currently available to the companys management readers should not put undue reliance on these forwardlooking statements forwardlooking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified spectrum pharmaceuticals incs actual results may differ materially from the results projected in the forwardlooking statements factors that might cause such a difference include but are not limited to those discussed in the companys most recent form k and qs we do not plan to update any such forwardlooking statements and expressly disclaim any duty to update the information contained in this filing except as required by law all contents copyright spectrum pharmaceuticals inc   all rights reserved ppall site map  privacy policy  terms of use  linking policycontact us  webmail spectrum pharmaceuticals inc  investor relations our company our company company philosophy partnerships management board of directors careers product portfolio product portfolio commercial latestage rolontistm eflapegrastim qapzolatm apaziquone development poziotinib outlicensing glossary product returns evomela product returns folotyn product returns marqibo water bath kit destruction verification form marqibo equipment decontamination verification and shipment preparation marqibo instruction for sites to return usedunused material to almac clinical services fusilev  beleodaq product returns zevalin product returns investor relations investor relations press releases events and presentations corporate governance management board of directors committee composition insider transactions annual report and proxy information financial information sec filings k annual reports quarterly results financial statements stock information historic stock lookup investment calculator stocksplit history analyst coverage ownership profile investor faqs litigation documents patient assistance medical professionals medical professionals clinical trials grants investigator initiated trials careers contact us nasdaq sppi    day high  day low  volume  provided by esignal  pm et on jul   home  investor relations corporate profile spectrum pharmaceuticals is a leading biotechnology company with a focus in oncology and hematology the companys strategy is comprised of acquiring and developing a broad and diverse pipeline of latestage clinical and commercial products establishing a commercial organization for its approved drugs continuing to build a team with people who have demonstrated skills passion commitment and have a track record of success in its areas of focus and leveraging the expertise of partners around the world to assist it in the execution of its strategy spectrum pharmaceuticals stock is traded through the nasdaq global market system ticker symbol sppi recent releases july   henderson nevbusiness wire spectrum pharmaceuticals nasdaqgs sppi a biotechnolo june   the folotyn antifolate and an hdac inhibitor romidepsin combination was shown to achi june   henderson nevbusiness wire spectrum pharmaceuticals inc nasdaqgs sppi a biote view all back to top intra  mo  mo  yr contact ir irsppirxcom shareholder tools search ir our company company philosophy partnerships management board of directors careers product portfolio commercial latestagedevelopment outlicensing glossary investor relations press releases events and presentations corporate governance annual report and proxy information financial information stock information investor faqs litigation documents patient assistance star medical professionals clinical trials medical affairs grants investigator initiated trials careers contact us this web site contains forwardlooking statements within the meaning of section a of the securities act of  as amended and section e of the securities exchange act of  as amended and in reliance upon the safe harbor provisions of the private securities litigation reform act of  such forwardlooking statements are based on the beliefs of the companys management as well as assumptions made by and information currently available to the companys management readers should not put undue reliance on these forwardlooking statements forwardlooking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified spectrum pharmaceuticals incs actual results may differ materially from the results projected in the forwardlooking statements factors that might cause such a difference include but are not limited to those discussed in the companys most recent form k and qs we do not plan to update any such forwardlooking statements and expressly disclaim any duty to update the information contained in this filing except as required by law all contents copyright spectrum pharmaceuticals inc   all rights reserved ppall site map  privacy policy  terms of use  linking policy  contact us remote support  clinical support  webmail spectrum pharmaceuticals inc  management our company our company company philosophy partnerships management board of directors careers product portfolio product portfolio commercial latestage rolontistm eflapegrastim qapzolatm apaziquone development poziotinib outlicensing glossary product returns evomela product returns folotyn product returns marqibo water bath kit destruction verification form marqibo equipment decontamination verification and shipment preparation marqibo instruction for sites to return usedunused material to almac clinical services fusilev  beleodaq product returns zevalin product returns investor relations investor relations press releases events and presentations corporate governance management board of directors committee composition insider transactions annual report and proxy information financial information sec filings k annual reports quarterly results financial statements stock information historic stock lookup investment calculator stocksplit history analyst coverage ownership profile investor faqs litigation documents patient assistance medical professionals medical professionals clinical trials grants investigator initiated trials careers contact us home  investor relations  corporate governance  management management display all bios show all hide all rajesh c shrotriya md chairman and chief executive officer in september  dr shrotriya joined the company as president and chief operating officer and in august  he was appointed chief executive officer in this capacity he has spearheaded major changes in business strategy and coordinated structural reorganization culminating in the formation of spectrum pharmaceuticals inc previously dr shrotriya was executive vice president and chief scientific officer for supergen inc and vice president medical affairs and vice president chief medical officer at mgi pharma inc for  years he held various positions at bristolmyers squibb company the most recent being executive director worldwide cns clinical research dr shrotriya is a  ernst  young orange county region entrepreneur of the year® award winner dr shrotriya was specifically cited for his turnaround of spectrum the ernst  young llp award program recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation financial performance and personal commitment to their businesses and communities dr shrotriya was chosen from  finalists by a panel of independent judges joseph w turgeon president and chief operating officer mr  turgeon has global responsibility for leading commercial operations medical and clinical development and pharmaceutical operations prior to joining the company mr turgeon spent  years at amgen inc as vice president sales where he built and led the sales organization across multiple areas including oncology inflammation and bone health  mr turgeon was responsible for launching most of the drugs and their dramatic growth at amgen  he brings depth of experience in the oncology marketplace mr turgeon holds a bs from jacksonville university where he studied microbiology and economics kurt a gustafson executive vice president chief financial officer and principal accounting officer mr gustafson has more than  years of diverse experience in corporate finance with  years in senior management roles leading the finance departments of multifaceted dynamic and growth oriented biopharmaceutical industry organizations prior to joining spectrum mr gustafson served as vice president and chief financial officer at halozyme therapeutics inc a publiclytraded biopharmaceutical company where he managed several successful financings and established a three year midrange planning process to align resource allocations to long term strategic goals before halozyme mr gustafson worked at amgen for over  years most recently as vice president finance with responsibility for financial planning and cost accounting for worldwide manufacturing covering seven manufacturing sites during his tenure at amgen mr gustafson also served as cfo of amgen international and resided in zug switzerland mr gustafson holds a bachelors of arts degree in accounting from north park university in chicago and a masters in business administration from university of california los angeles thomas j riga executive vice president chief commercial officer and head of business development mr riga is responsible for the commercialization and sales of all spectrum products in us and globally mr riga brings over  years of experience in the pharmaceutical and biotechnology industry  his experience spans sales marketing manufacturing and corporate accounts  throughout his career tom has delivered top tier results in a variety of functional areas within commercial     pramod k gupta phd senior vice president pharmaceutical operations pramod gupta is responsible for product development and commercial manufacturing and supply chain of spectrum products his product development responsibilities include chemical development formulation development analytical development scaleupmanufacturing stability studies clinical supplies and intellectual property  his supply chain responsibilities include commercial product inventory management product manufacturing and shipment and contracts management pramod has over  years’ experience in the pharmaceutical industry including abbott baxter and bausch  lomb where he held positions of increasing responsibilities  he has been part of over  approved ndas and over  product launches globally  pramod holds phd in pharmaceutical sciences has published more than  papers and  scientific books and holds over  granted patents  he has also served as an expert committee member for the united states pharmacopoeia zane yang md senior vice president clinical development dr yang joins spectrum from inovio pharmaceuticals where he was vice president clinical development oncology for inovios entire oncology therapeutic area he led inovios clinical development for all oncology immunotherapies and cancer vaccines as well as all collaborative activities with external organizations  prior to inovio he was director of medical affairs and clinical development at janssen novartis oncology and merck  co   dr yang who earned his md at beijing medical university was a fellow at emory universitys winship cancer institute university of pennsylvania and the wistar institute in philadelphia before transitioning to the pharmaceutical industry he was associate professor at the university of virginia medical center in charlottesville va avi n oler cfa vice president operations and chief of staff to the ceo lisa a croissant vice president sales bimal r shah vice president corporate and business development back to top nasdaq sppi price  change   day high  day low  volume   pm et on jul   delayed at least  minutesprovided by esignal shareholder tools search ir our company company philosophy partnerships management board of directors careers product portfolio commercial latestagedevelopment outlicensing glossary investor relations press releases events and presentations corporate governance annual report and proxy information financial information stock information investor faqs litigation documents patient assistance star medical professionals clinical trials medical affairs grants investigator initiated trials careers contact us this web site contains forwardlooking statements within the meaning of section a of the securities act of  as amended and section e of the securities exchange act of  as amended and in reliance upon the safe harbor provisions of the private securities litigation reform act of  such forwardlooking statements are based on the beliefs of the companys management as well as assumptions made by and information currently available to the companys management readers should not put undue reliance on these forwardlooking statements forwardlooking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified spectrum pharmaceuticals incs actual results may differ materially from the results projected in the forwardlooking statements factors that might cause such a difference include but are not limited to those discussed in the companys most recent form k and qs we do not plan to update any such forwardlooking statements and expressly disclaim any duty to update the information contained in this filing except as required by law all contents copyright spectrum pharmaceuticals inc   all rights reserved ppall site map  privacy policy  terms of use  linking policy  contact us remote support  clinical support  webmail spectrum pharmaceuticals inc  product pipeline review    rnr market research advanced search     salesrnrmarketresearchcom search market research reports ﻿ market research assistance salesrnrmarketresearchcom on the web related markets anesthesia drugsbiosimilarbiopharmaceuticalsclinical trialdietary supplementsdietary supplementdiseases  treatmentcancer drugsdiabetes drugshypertension drugshiv related market reportsperipheral tcell lymphoma  competitive landscape market insights epidemiology and market forecastglobal cancer supportive care therapeutics market to   patent expirations create opportunities for biosimilars in the chemotherapy induced anemia and neutropenia marketsspectrum pharmaceuticals inc  product pipeline review  opportunityanalyzer hyperparathyroidism  opportunity analysis and forecasts to spectrum pharmaceuticals inc  product pipeline review   home  life sciences  pharmaceuticals  biopharmaceuticals  report detail spectrum pharmaceuticals inc  product pipeline review   publisher name  global markets direct date apr no of pages  price single user license us  corporate user license us  report descriptiontable of contentnews  blogother reportsour offerings global markets directs spectrum pharmaceuticals inc  product pipeline review   provides an overview of the spectrum pharmaceuticals incs pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of spectrum pharmaceuticals incs complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets directs report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets directs proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets directs team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope the report provides brief overview of spectrum pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of spectrum pharmaceuticals incs human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the products developmental history and major milestones special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement latest news and deals relating to the spectrum pharmaceuticals incs pipeline products reasons to buy evaluate spectrum pharmaceuticals incs strategic position with total access to detailed information on its product pipeline assess the growth potential of spectrum pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the spectrum pharmaceuticals incs rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of spectrum pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of spectrum pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of spectrum pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues spectrum pharmaceuticals inc  product pipeline review   table of contents table of contents  list of tables  list of figures  spectrum pharmaceuticals inc snapshot  spectrum pharmaceuticals inc overview  key information  key facts  spectrum pharmaceuticals inc  research and development overview  key therapeutic areas  spectrum pharmaceuticals inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  partnered products  partnered productscombination treatment modalities  spectrum pharmaceuticals inc  pipeline products glance  spectrum pharmaceuticals inc  late stage pipeline products  preregistration productscombination treatment modalities  phase iii productscombination treatment modalities  spectrum pharmaceuticals inc  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  spectrum pharmaceuticals inc  early stage pipeline products  preclinical productscombination treatment modalities  spectrum pharmaceuticals inc  unknown stage pipeline products  unknown productscombination treatment modalities  spectrum pharmaceuticals inc  drug profiles  melphalan  product description  mechanism of action  rd progress  apaziquone  product description  mechanism of action  rd progress  pralatrexate  product description  mechanism of action  rd progress  vincristine sulfate  product description  mechanism of action  rd progress  yttritum  ibritumomab tiuxetan  product description  mechanism of action  rd progress  belinostat  product description  mechanism of action  rd progress  lucanthone hydrochloride  product description  mechanism of action  rd progress  menadione  product description  mechanism of action  rd progress  ortataxel  product description  mechanism of action  rd progress  ozarelix  product description  mechanism of action  rd progress  spi  product description  mechanism of action  rd progress  spi  product description  mechanism of action  rd progress  mtrn  product description  mechanism of action  rd progress  spi  product description  mechanism of action  rd progress  topotecan hydrochloride liposomal  product description  mechanism of action  rd progress  vinorelbine tartrate liposomal  product description  mechanism of action  rd progress  rituximab biosimilar  product description  mechanism of action  rd progress  spectrum pharmaceuticals inc  pipeline analysis  spectrum pharmaceuticals inc  pipeline products by target  spectrum pharmaceuticals inc  pipeline products by route of administration  spectrum pharmaceuticals inc  pipeline products by molecule type  spectrum pharmaceuticals inc  pipeline products by mechanism of action  spectrum pharmaceuticals inc  recent pipeline updates  spectrum pharmaceuticals inc  dormant projects  spectrum pharmaceuticals inc  discontinued pipeline products  discontinued pipeline product profiles  efaproxiral  ortataxel  rh  spectrum pharmaceuticals inc  company statement  spectrum pharmaceuticals inc  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables spectrum pharmaceuticals inc key information  spectrum pharmaceuticals inc key facts  spectrum pharmaceuticals inc  pipeline by indication   spectrum pharmaceuticals inc  pipeline by stage of development   spectrum pharmaceuticals inc  monotherapy products in pipeline   spectrum pharmaceuticals inc  partnered products in pipeline   spectrum pharmaceuticals inc  partnered products combination treatment modalities   spectrum pharmaceuticals inc  preregistration   spectrum pharmaceuticals inc  phase iii   spectrum pharmaceuticals inc  phase ii   spectrum pharmaceuticals inc  phase i   spectrum pharmaceuticals inc  preclinical   spectrum pharmaceuticals inc  unknown   spectrum pharmaceuticals inc  pipeline by target   spectrum pharmaceuticals inc  pipeline by route of administration   spectrum pharmaceuticals inc  pipeline by molecule type   spectrum pharmaceuticals inc  pipeline products by mechanism of action   spectrum pharmaceuticals inc  recent pipeline updates   spectrum pharmaceuticals inc  dormant developmental projects  spectrum pharmaceuticals inc  discontinued pipeline products   spectrum pharmaceuticals inc other locations  spectrum pharmaceuticals inc subsidiaries  list of figures spectrum pharmaceuticals inc  pipeline by top  indication   spectrum pharmaceuticals inc  pipeline by stage of development   spectrum pharmaceuticals inc  monotherapy products in pipeline   spectrum pharmaceuticals inc  partnered products in pipeline   spectrum pharmaceuticals inc  pipeline by top  target   spectrum pharmaceuticals inc  pipeline by top  route of administration   spectrum pharmaceuticals inc  pipeline by top  molecule type   spectrum pharmaceuticals inc  pipeline products by top  mechanism of action   renewable energy sources needs to boost global microgrids marketthe global market for microgrid was worth us billion in  and is anticipated to touch an estimate of us billion by  dealers in the market for microgrids are incessantly improving the network hostinghellipmanufacturing trends in the coming daysthe manufacturing industry may be encountering some breezes but it is irrefutably in the middle of a technological revival that is altering the appearance structures and practices of the modern factory notwithstanding the jeopardies andhelliptop  emerging technologiesthe world economic forum wef and scientific american lately unveiled the major technological innovation list of the top ten emerging technologies this list emphasizes on the technological developments which have the supremacy to transform industrieshellipglobal biosimilars market to be led by novartis by biologics which are typically inoculated or injected are formed in living entities making them more challenging and costly to manufacture than the usual pills contrived from chemicals observing that mockups are mostly identical to thehellipglobal thyroid gland disorder treatment market to grow steadilythe global thyroid gland disorder treatment market was worth us billion in  and is projected to reach a market value of us billion in  intensifying at a cagr of  from  to   thehellip highspeed data transmission and high volume needs propel fiber optic connectors market fiber optic connectors are a substantial fragment of the global telecommunication industry optical fibers are joined using fiber optic connectors which allow the light conduction between two consecutive optical fibers an additional im…extensive use of digital technologies for diagnostic applications to boost global optical imaging market the global optical imaging system market is predicted to reach us  billion by  it is expected to grow at a stable rate and will post a cagr of more than  in the coming years the growing market infiltration of digital …foremost trends in global pet care market the global pet care market is foretold to improve in the forthcoming years as matched to the preceding years and will showcase better sales in various market segments it is estimated that the global pet care market will grow at a cagr o…china to review its food security laws china has arisen as the globe’s firmest developing economy in addition china brags about the biggest population pool in the world in recent times the one child policy in the republic was terminated this is anticipated to upsur…improving standards of living to boost global consumer durables market consumer durables is a cataloguing of consumer goods that are not essential to be bought very often as they are fashioned in a way so as to last for an extended period of time profits in the consumer durables sector were most profoundly… global and chinese biopharmaceuticals industry  market research report published jun        price us  onwards        pages  the global and chinese biopharmaceuticals industry  market research report is a professional and indepth study on the current state of the global biopharmaceuticals industry with a focus on the chinese market the report provides key statistics on the market status of the biopharmaceuticals manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industryfirstly the report provides a basic overview of the industry including i bio industry markets in china published may        price us  onwards        pages  chinas demand for bio industry has grown at a fast pace in the past decade in the next decade both production and demand will continue to grow the chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output imports  exports consumer consumption and capital investment for over two decades this new study examines chinas economic trends investment environment industry development supply and demand industry capacity industry biotechnology products companies in china published may        price us  onwards        pages  this study focuses on chinas biotechnology products industry assessments and company profiles in the two past decades the industry has been growing at a fast pace the dramatic expansions of the manufacturing capabilities and rising consumer consumptions in china have transformed chinas society and economy china is one of the worlds major producers for industrial and consumer products far outpacing other economies in the world china is the worlds fastest growing market for the consumpti biotechnology products industry industry forecasts  china focus published may        price us  onwards        pages  this study focuses on chinas biotechnology products industry forecasts in the two past decades the industry has been growing at a fast pace the dramatic expansions of the manufacturing capabilities and rising consumer consumptions in china have transformed chinas society and economy china is one of the worlds major producers for industrial and consumer products far outpacing other economies in the world china is the worlds fastest growing market for the consumptions of goods and servic emea europe middle east and africa biochar market report  published apr        price us  onwards        pages  in this report the emea biochar market is valued at usd xx million in  and is expected to reach usd xx million by the end of  growing at a cagr of xx between  and  geographically this report split emea into europe the middle east and africa with sales mt revenue million usd market share and growth rate of biochar for these regions from  to  forecast  europe germany france uk russia italy and benelux  middle east saudi  actelion partnering deals and alliances  to  published apr        price us  onwards        pages  delivery of this report will take  days after purchase this report provides all the information you require to better understand actelion and its partnering interests and activities since  the partnering deals and alliance since  report provides an indepth insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of the most up to  alkermes partnering deals and alliances  to  published apr        price us  onwards        pages  delivery of this report will take  days after purchase this report provides all the information you require to better understand alkermes and its partnering interests and activities since  the partnering deals and alliance since  report provides an indepth insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of the most up to  amylin pharmaceuticals partnering deals and alliances  to  published apr        price us  onwards        pages  delivery of this report will take  days after purchase this report provides all the information you require to better understand amylin pharmaceuticals and its partnering interests and activities since  the partnering deals and alliance since  report provides an indepth insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of t astrazeneca partnering deals and alliances  to  published apr        price us  onwards        pages  delivery of this report will take  days after purchase this report provides all the information you require to better understand astrazeneca and its partnering interests and activities since  the partnering deals and alliance since  report provides an indepth insight into the partnering activity of one of the worlds leading life sciences companies on demand company reports are prepared upon purchase to ensure inclusion of the most up services value for money we believe in optimum utilization of available budget and resources while servicing our clients your market research requirements we keep the same approach in focus to help you get the best value for your s ever growing inventory ranging from the smallest feasible  required data datasheets data facts swot analysis company profiles etc to full research reports that help you make decisions our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than  niche sectors one stop solution need a custom research report on medical devices market require all available business intelligence on d printing industry exploring fb sector of a particular countryregion rnrmarketresearchcom is your onestopsolution to all market intelligence needs we not only offer custom research and consulting services we also bundle reports to meet your needs and help you fetch the data analysis you require for your business dedicated client engagement not limited to only finding relevant reports for you our client engagement team dedicates its efforts to understand your business need and accordingly maps available research data to help you move forward call your client engagement executive any time of your day and get your questions answered in order to make the correct business decision saving time and efforts simply share your research requirement details with us and let us do all the hard work to find required intelligence for you when you add up our one stop solution and dedicated client engagement services mentioned above you obviously know the time and effort saving you do by working with us payment flexibility working with fortune  organizations we understand the importance of being flexible for payments share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done postpurchase research support have questions after reading a report  datasheet bought through us not sure about the methodology used for data available in the research talk to us  share your questions with us and if required we will connect you with the analystsauthors of the reports and ensure you get satisfactory answers for the same need more data  analysis  reports on the topic of your researchproject the rnrmarketresearchcom team is here for you x to support you with your postpurchase requirements subscription offers  packages get in touch with us for more details  salesrnrmarketresearchcom       ad hoc pay  as  you  go  bucket subscriptions fixed cost for of reports customize  personalize as per your needs avail upto  discount on below publisher reports azoth analytics technavio spectrum pharmaceuticals inc  management our company our company company philosophy partnerships management board of directors careers product portfolio product portfolio commercial latestage rolontistm eflapegrastim qapzolatm apaziquone development poziotinib outlicensing glossary product returns evomela product returns folotyn product returns marqibo water bath kit destruction verification form marqibo equipment decontamination verification and shipment preparation marqibo instruction for sites to return usedunused material to almac clinical services fusilev  beleodaq product returns zevalin product returns investor relations investor relations press releases events and presentations corporate governance management board of directors committee composition insider transactions annual report and proxy information financial information sec filings k annual reports quarterly results financial statements stock information historic stock lookup investment calculator stocksplit history analyst coverage ownership profile investor faqs litigation documents patient assistance medical professionals medical professionals clinical trials grants investigator initiated trials careers contact us home  investor relations  corporate governance  management management display all bios show all hide all rajesh c shrotriya md chairman and chief executive officer in september  dr shrotriya joined the company as president and chief operating officer and in august  he was appointed chief executive officer in this capacity he has spearheaded major changes in business strategy and coordinated structural reorganization culminating in the formation of spectrum pharmaceuticals inc previously dr shrotriya was executive vice president and chief scientific officer for supergen inc and vice president medical affairs and vice president chief medical officer at mgi pharma inc for  years he held various positions at bristolmyers squibb company the most recent being executive director worldwide cns clinical research dr shrotriya is a  ernst  young orange county region entrepreneur of the year® award winner dr shrotriya was specifically cited for his turnaround of spectrum the ernst  young llp award program recognizes entrepreneurs who demonstrate excellence and extraordinary success in such areas as innovation financial performance and personal commitment to their businesses and communities dr shrotriya was chosen from  finalists by a panel of independent judges joseph w turgeon president and chief operating officer mr  turgeon has global responsibility for leading commercial operations medical and clinical development and pharmaceutical operations prior to joining the company mr turgeon spent  years at amgen inc as vice president sales where he built and led the sales organization across multiple areas including oncology inflammation and bone health  mr turgeon was responsible for launching most of the drugs and their dramatic growth at amgen  he brings depth of experience in the oncology marketplace mr turgeon holds a bs from jacksonville university where he studied microbiology and economics kurt a gustafson executive vice president chief financial officer and principal accounting officer mr gustafson has more than  years of diverse experience in corporate finance with  years in senior management roles leading the finance departments of multifaceted dynamic and growth oriented biopharmaceutical industry organizations prior to joining spectrum mr gustafson served as vice president and chief financial officer at halozyme therapeutics inc a publiclytraded biopharmaceutical company where he managed several successful financings and established a three year midrange planning process to align resource allocations to long term strategic goals before halozyme mr gustafson worked at amgen for over  years most recently as vice president finance with responsibility for financial planning and cost accounting for worldwide manufacturing covering seven manufacturing sites during his tenure at amgen mr gustafson also served as cfo of amgen international and resided in zug switzerland mr gustafson holds a bachelors of arts degree in accounting from north park university in chicago and a masters in business administration from university of california los angeles thomas j riga executive vice president chief commercial officer and head of business development mr riga is responsible for the commercialization and sales of all spectrum products in us and globally mr riga brings over  years of experience in the pharmaceutical and biotechnology industry  his experience spans sales marketing manufacturing and corporate accounts  throughout his career tom has delivered top tier results in a variety of functional areas within commercial     pramod k gupta phd senior vice president pharmaceutical operations pramod gupta is responsible for product development and commercial manufacturing and supply chain of spectrum products his product development responsibilities include chemical development formulation development analytical development scaleupmanufacturing stability studies clinical supplies and intellectual property  his supply chain responsibilities include commercial product inventory management product manufacturing and shipment and contracts management pramod has over  years’ experience in the pharmaceutical industry including abbott baxter and bausch  lomb where he held positions of increasing responsibilities  he has been part of over  approved ndas and over  product launches globally  pramod holds phd in pharmaceutical sciences has published more than  papers and  scientific books and holds over  granted patents  he has also served as an expert committee member for the united states pharmacopoeia zane yang md senior vice president clinical development dr yang joins spectrum from inovio pharmaceuticals where he was vice president clinical development oncology for inovios entire oncology therapeutic area he led inovios clinical development for all oncology immunotherapies and cancer vaccines as well as all collaborative activities with external organizations  prior to inovio he was director of medical affairs and clinical development at janssen novartis oncology and merck  co   dr yang who earned his md at beijing medical university was a fellow at emory universitys winship cancer institute university of pennsylvania and the wistar institute in philadelphia before transitioning to the pharmaceutical industry he was associate professor at the university of virginia medical center in charlottesville va avi n oler cfa vice president operations and chief of staff to the ceo lisa a croissant vice president sales bimal r shah vice president corporate and business development back to top nasdaq sppi price  change   day high  day low  volume   pm et on jul   delayed at least  minutesprovided by esignal shareholder tools search ir our company company philosophy partnerships management board of directors careers product portfolio commercial latestagedevelopment outlicensing glossary investor relations press releases events and presentations corporate governance annual report and proxy information financial information stock information investor faqs litigation documents patient assistance star medical professionals clinical trials medical affairs grants investigator initiated trials careers contact us this web site contains forwardlooking statements within the meaning of section a of the securities act of  as amended and section e of the securities exchange act of  as amended and in reliance upon the safe harbor provisions of the private securities litigation reform act of  such forwardlooking statements are based on the beliefs of the companys management as well as assumptions made by and information currently available to the companys management readers should not put undue reliance on these forwardlooking statements forwardlooking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified spectrum pharmaceuticals incs actual results may differ materially from the results projected in the forwardlooking statements factors that might cause such a difference include but are not limited to those discussed in the companys most recent form k and qs we do not plan to update any such forwardlooking statements and expressly disclaim any duty to update the information contained in this filing except as required by law all contents copyright spectrum pharmaceuticals inc   all rights reserved ppall site map  privacy policy  terms of use  linking policy  contact us remote support  clinical support  webmail microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft spectrum pharmaceuticals inc  product pipeline review   trends statistics segment and forecasts market size share analysis  market research store     gmt office hours  uscan toll free  us office no home categories become publisher news about us contact us select category consumer goods food  beverage heavy industry life sciences marketing  market research public sector service industries technology  media semiconductor chemical and materials metallurgical market research search home  life sciences  pharmaceuticals spectrum pharmaceuticals inc  product pipeline review   published apr  format pdf  global markets direct  number of pages   code mrs   report details table of content inquiry for buying request sample spectrum pharmaceuticals inc  product pipeline review   summary global markets direct’s ‘spectrum pharmaceuticals inc  product pipeline review  ’ provides an overview of the spectrum pharmaceuticals inc’s pharmaceutical research and development focus this report provides comprehensive information on the current therapeutic developmental pipeline of spectrum pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projects global markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis the report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass products note certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease scope  the report provides brief overview of spectrum pharmaceuticals inc including business description key information and facts and its locations and subsidiaries  the report reviews current pipeline of spectrum pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects  the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio  the report summarizes all the dormant and discontinued pipeline projects  latest company statement  latest news and deals relating to the spectrum pharmaceuticals inc’s pipeline products reasons to buy  evaluate spectrum pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline  assess the growth potential of spectrum pharmaceuticals inc in its therapy areas of focus  identify new drug targets and therapeutic classes in the spectrum pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas  exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps  develop strategic initiatives by understanding the focus areas of spectrum pharmaceuticals inc and exploit collaboration and partnership opportunities  identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage  plan mergers and acquisitions effectively by identifying the most promising pipeline of spectrum pharmaceuticals inc  develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope  explore the dormant and discontinued projects of spectrum pharmaceuticals inc and identify potential opportunities in those areas  avoid intellectual property rights related issues table of contents table of contents  list of tables  list of figures  spectrum pharmaceuticals inc snapshot  spectrum pharmaceuticals inc overview  key information  key facts  spectrum pharmaceuticals inc  research and development overview  key therapeutic areas  spectrum pharmaceuticals inc  pipeline review  pipeline products by stage of development  pipeline products  monotherapy  pipeline products  partnered products  partnered productscombination treatment modalities  spectrum pharmaceuticals inc  pipeline products glance  spectrum pharmaceuticals inc  late stage pipeline products  preregistration productscombination treatment modalities  phase iii productscombination treatment modalities  spectrum pharmaceuticals inc  clinical stage pipeline products  phase ii productscombination treatment modalities  phase i productscombination treatment modalities  spectrum pharmaceuticals inc  early stage pipeline products  preclinical productscombination treatment modalities  spectrum pharmaceuticals inc  unknown stage pipeline products  unknown productscombination treatment modalities  spectrum pharmaceuticals inc  drug profiles  melphalan  product description  mechanism of action  rd progress  apaziquone  product description  mechanism of action  rd progress  pralatrexate  product description  mechanism of action  rd progress  vincristine sulfate  product description  mechanism of action  rd progress  yttritum  ibritumomab tiuxetan  product description  mechanism of action  rd progress  belinostat  product description  mechanism of action  rd progress  lucanthone hydrochloride  product description  mechanism of action  rd progress  menadione  product description  mechanism of action  rd progress  ortataxel  product description  mechanism of action  rd progress  ozarelix  product description  mechanism of action  rd progress  spi  product description  mechanism of action  rd progress  spi  product description  mechanism of action  rd progress  mtrn  product description  mechanism of action  rd progress  spi  product description  mechanism of action  rd progress  topotecan hydrochloride liposomal  product description  mechanism of action  rd progress  vinorelbine tartrate liposomal  product description  mechanism of action  rd progress  rituximab biosimilar  product description  mechanism of action  rd progress  spectrum pharmaceuticals inc  pipeline analysis  spectrum pharmaceuticals inc  pipeline products by target  spectrum pharmaceuticals inc  pipeline products by route of administration  spectrum pharmaceuticals inc  pipeline products by molecule type  spectrum pharmaceuticals inc  pipeline products by mechanism of action  spectrum pharmaceuticals inc  recent pipeline updates  spectrum pharmaceuticals inc  dormant projects  spectrum pharmaceuticals inc  discontinued pipeline products  discontinued pipeline product profiles  efaproxiral  ortataxel  rh  spectrum pharmaceuticals inc  company statement  spectrum pharmaceuticals inc  locations and subsidiaries  head office  other locations  subsidiaries  appendix  methodology  coverage  secondary research  primary research  expert panel validation  contact us  disclaimer  list of tables spectrum pharmaceuticals inc key information  spectrum pharmaceuticals inc key facts  spectrum pharmaceuticals inc  pipeline by indication   spectrum pharmaceuticals inc  pipeline by stage of development   spectrum pharmaceuticals inc  monotherapy products in pipeline   spectrum pharmaceuticals inc  partnered products in pipeline   spectrum pharmaceuticals inc  partnered products combination treatment modalities   spectrum pharmaceuticals inc  preregistration   spectrum pharmaceuticals inc  phase iii   spectrum pharmaceuticals inc  phase ii   spectrum pharmaceuticals inc  phase i   spectrum pharmaceuticals inc  preclinical   spectrum pharmaceuticals inc  unknown   spectrum pharmaceuticals inc  pipeline by target   spectrum pharmaceuticals inc  pipeline by route of administration   spectrum pharmaceuticals inc  pipeline by molecule type   spectrum pharmaceuticals inc  pipeline products by mechanism of action   spectrum pharmaceuticals inc  recent pipeline updates   spectrum pharmaceuticals inc  dormant developmental projects  spectrum pharmaceuticals inc  discontinued pipeline products   spectrum pharmaceuticals inc other locations  spectrum pharmaceuticals inc subsidiaries  list of figures spectrum pharmaceuticals inc  pipeline by top  indication   spectrum pharmaceuticals inc  pipeline by stage of development   spectrum pharmaceuticals inc  monotherapy products in pipeline   spectrum pharmaceuticals inc  partnered products in pipeline   spectrum pharmaceuticals inc  pipeline by top  target   spectrum pharmaceuticals inc  pipeline by top  route of administration   spectrum pharmaceuticals inc  pipeline by top  molecule type   spectrum pharmaceuticals inc  pipeline products by top  mechanism of action   inquiry for buying please fill your details below to inquire about this report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit request sample please fill your details below to receive sample report  indicates required fields name email phone name of company titledesignation country name select country andorra united arab emirates afghanistan antigua and barbuda anguilla albania armenia angola antarctica argentina american samoa austria australia aruba åland islands azerbaijan bosnia and herzegovina barbados bangladesh belgium burkina faso bulgaria bahrain burundi benin saint barthélemy bermuda brunei darussalam bolivia plurinational state of bonaire sint eustatius and saba brazil bahamas bhutan bouvet island botswana belarus belize canada cocos keeling islands congo the democratic republic of the central african republic congo switzerland côte divoire cook islands chile cameroon china colombia costa rica cuba cape verde curaçao christmas island cyprus czech republic germany djibouti denmark dominica dominican republic algeria ecuador estonia egypt western sahara eritrea spain ethiopia finland fiji falkland islands malvinas micronesia federated states of faroe islands france gabon united kingdom grenada georgia french guiana guernsey ghana gibraltar greenland gambia guinea guadeloupe equatorial guinea greece south georgia and the south sandwich islands guatemala guam guineabissau guyana hong kong heard island and mcdonald islands honduras croatia haiti hungary indonesia ireland israel isle of man india british indian ocean territory iraq iran islamic republic of iceland italy jersey jamaica jordan japan kenya kyrgyzstan cambodia kiribati comoros saint kitts and nevis korea democratic peoples republic of korea republic of kuwait cayman islands kazakhstan lao peoples democratic republic lebanon saint lucia liechtenstein sri lanka liberia lesotho lithuania luxembourg latvia libya morocco monaco moldova republic of montenegro saint martin french part madagascar marshall islands macedonia the former yugoslav republic of mali myanmar mongolia macao northern mariana islands martinique mauritania montserrat malta mauritius maldives malawi mexico malaysia mozambique namibia new caledonia niger norfolk island nigeria nicaragua netherlands norway nepal nauru niue new zealand oman panama peru french polynesia papua new guinea philippines pakistan poland saint pierre and miquelon pitcairn puerto rico palestinian state of portugal palau paraguay qatar réunion romania serbia russian federation rwanda saudi arabia solomon islands seychelles sudan sweden singapore saint helena ascension and tristan da cunha slovenia svalbard and jan mayen slovakia sierra leone san marino senegal somalia suriname south sudan sao tome and principe el salvador sint maarten dutch part syrian arab republic swaziland turks and caicos islands chad french southern territories togo thailand tajikistan tokelau timorleste turkmenistan tunisia tonga turkey trinidad and tobago tuvalu taiwan province of china tanzania united republic of ukraine uganda united states minor outlying islands united states uruguay uzbekistan holy see vatican city state saint vincent and the grenadines venezuela bolivarian republic of virgin islands british virgin islands us viet nam vanuatu wallis and futuna samoa yemen mayotte south africa zambia zimbabwe how can we help you refresh captcha submit related reports global and europe bcg vaccine market  analysis and outlook to  jul  eu research  pages    code  mrs   this report presents a comprehensive overview of the bcg vaccine market in europe this shares the history data information from  to  and forecast from  to  this report provides a detailed analysis of the market its dynamics structure characteristics main players growth and demand drivers etc as a detailed analysis report it covers all details inside analysis and opinion in bcg vaccine industry this report focus global and europe market it covers details playe read more global onychomycosis tinea unguium drug detailed analysis report  jul  detailed analysis research  pages    code  mrs   this report splits onychomycosis tinea unguium drug by product drug form by product usage type this shares the history data information from  to  and forecast from  to  and this report mainly introduces volume and value market share by players by regions by product type by consumers and also their price change details as a detailed analysis report it covers all details inside analysis and opinion in onychomycosis tinea unguium drug industry this report fo read more life science analytics  global market outlook  jun  stratistics mrc  pages    code  mrs   according to stratistics mrc the global life science analytics market is expected to grow from  billion in  to reach  billion by  with a cagr of  some of the factors propelling the market growth are raising demand for analytics in sales and marketing applications increasing need of these solutions especially in clinical trials and improvements in technological advancements however lack of skilled professionals huge implementation costs and financial limitations read more chronic kidney disease ckd drugs  global market outlook  jul  stratistics mrc  pages    code  mrs   according to stratistics mrc the global chronic kidney disease ckd drugs market is expected to grow from  billion in  to reach  billion by  with a cagr of  drivers that are shaping the global market include growing incidences of chronic kidney diseases rise in aged population rising incidence of diabetes and obesity related disorders significant unmet requirements and beneficial reimbursement policies on the other hand factors such as intense competition fr read more acaricides  global market outlook  jul  stratistics mrc  pages    code  mrs   according to stratistics mrc the global acaricides market is expected to grow from  million in  to reach  million by  with a cagr of  high demand for meat dairy products and crops growth in crop protection industry and rise in productivity are some of the factors propelling the market growth however increase in cost alternative acaricides sources and regulatory restrictions are the factors suppressing the market on the other hand expansion of bioactive aca read more global and united states bacillus subtilis depth research report  jul  united states research  pages    code  mrs   this report mainly introduces volume and value market share by players by regions by product type by consumers and also their price change details as a depth research report it covers all details inside analysis and opinion in bacillus subtilis industry this report focus united states market it covers details players regions product type and other details as following major companies bayer germany basf germany tonglu huifeng china kernel biotech china w read more global bacterial vaginosis drug market rport  jun  bisreport  pages    code  mrs   global bacterial vaginosis drug market report  full report  multi license section  section price as below page  chart and figure  publisher bisreport delivery time  hour contact salesbisreportcom phone  with the slowdown in world economic growth the bacterial vaginosis drug industry has also suffered a certain impact but still maintained a relatively optimistic growth the past four years bacterial vaginosis drug market size to maintain read more global alzheimers disease drug market rport  jun  bisreport  pages    code  mrs   global alzheimer’s disease drug market report  full report  multi license section  section price as below page  chart and figure  publisher bisreport delivery time  hour contact salesbisreportcom phone  with the slowdown in world economic growth the alzheimer’s disease drug industry has also suffered a certain impact but still maintained a relatively optimistic growth the past four years alzheimer’s disease drug market size to maintain read more global protein powder detailed analysis report  jul  detailed analysis research  pages    code  mrs   this report mainly introduces volume and value market share by players by regions by product type by consumers and also their price change details as a detailed analysis report it covers all details inside analysis and opinion in protein powder industry this report splits protein powder market price size first speciality second speciality protein powder flavors which covers the history data information from  to  and forecast from  to  this report focus glob read more opioidinduced constipation oic  pipeline review h  jul  global markets direct  pages    code  mrs   opioidinduced constipation oic  pipeline review h  summary global markets directs latest pharmaceutical and healthcare disease pipeline guide opioidinduced constipation oic  pipeline review h  provides an overview of the opioidinduced constipation oic toxicology pipeline landscape opioids are effective pain relievers but often have the side effect of constipation these medicines affect the gastrointestinal tract in a variety of ways opioids increase the amo read more payment mode single user  usd multi user  usd corporate user  usd latest report  global nonslip epoxy glass flake paint market research report  global parking sensors market research report  global nitrogen oxide sensor market research report  global nuclear density gauge market research report  global automotive interior materials market research report view more latest news global chitosan market set for rapid growth to reach usd  billion by  zion market research has published a new report titled chitosan market for water treatment biomed development of ecommerce to reshape global mobile hotspot router market mobile hotspot is a popular feature on smart phones that provide wireless internet access on many global carotenoids market is expected to reach around usd  billion in  zion market research has published a new report titled carotenoids market by type astaxanthin be soaring demand from food  beverages industry to act as prime driving for ascorbic acid market reports zion market research ascorbic acid is extensively available in nature mostly rich in leafy vegetables and fresh fruits global energy management system ems market is set for a rapid growth and is expected to reach usd  million by  zion market research has published a new report titled energy management system market ems by so view more single user  usd view pricing find help how to order disclaimer faqs return policy sitemap our company about us terms and conditions privacy policy we accept the following payment methods     market research store  market research reports sppi key statistics  spectrum pharmaceuticals inc financial ratios  marketwatch x tweet share this bulletin get news bulletins by email bulletin teavana shutdown by starbucks called latest mall casualty » investor alert new york markets close in market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close spectrum pharmaceuticals inc nasdaq sppi go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus spectrum pharmaceuticals inc market open  real time quotes jul    pm sppi quoteszigmancomposite   change   volume volume  real time quotes quoteszigmancomposite previous close     change   day low day high    week low  week high   company description spectrum pharmaceuticals inc engages in the acquisition development and commercialization of pipeline of latestage clinical and commercial products it targets nonhodgkins lymphoma advanced metastatic colorectal cancer acute lymphoblastic leukemia and multiple myeloma it operates through  spectrum pharmaceuticals inc engages in the acquisition development and commercialization of pipeline of latestage clinical and commercial products it targets nonhodgkins lymphoma advanced metastatic colorectal cancer acute lymphoblastic leukemia and multiple myeloma it operates through the following brands fusilev folotyn zevalin marqibo beleodaq evomela eoquin and renazorb the company was founded in december  and is headquartered in henderson nv valuation pe current  pe ratio with extraordinary items  price to sales ratio  price to book ratio  enterprise value to ebitda  enterprise value to sales  total debt to enterprise value  efficiency revenueemployee  income per employee  receivables turnover  total asset turnover  liquidity current ratio  quick ratio  cash ratio  profitability gross margin  operating margin  pretax margin  net margin  return on assets  return on equity  return on total capital  return on invested capital  capital structure total debt to total equity  total debt to total capital  total debt to total assets  longterm debt to equity  longterm debt to total capital  officers and executives name age officer since title dr rajesh c shrotriya   chairman  chief executive officer mr joseph g turgeon   president  chief operating officer mr kurt a gustafson   chief financial officer  executive vice president mr thomas j riga   chief commercial officer  senior vice president mr bimal r shah   vice presidentcorporate  business development insider actions – purchase – sale  – number of transactions  date name shares transaction value  stuart mitchell krassner director    derivativenonderivative trans at  per share   stuart mitchell krassner director    derivativenonderivative trans at  per share   anthony e maida director    derivativenonderivative trans at  per share   anthony e maida director    derivativenonderivative trans at  per share   stuart mitchell krassner director    derivativenonderivative trans at  per share   anthony e maida director    derivativenonderivative trans at  per share   luigi lenaz director    derivativenonderivative trans at  per share   stuart mitchell krassner director    derivativenonderivative trans at  per share   raymond wayne cohen director    derivativenonderivative trans at  per share   dolatrai vyas director    derivativenonderivative trans at  per share   anthony e maida director    derivativenonderivative trans at  per share   gilles r gagnon director    award at  per share   luigi lenaz director    award at  per share   stuart mitchell krassner director    award at  per share   raymond wayne cohen director    award at  per share   dolatrai vyas director    award at  per share   anthony e maida director    award at  per share   gilles r gagnon director    derivativenonderivative trans at  per share   luigi lenaz director    derivativenonderivative trans at  per share   stuart mitchell krassner director    derivativenonderivative trans at  per share   raymond wayne cohen director    derivativenonderivative trans at  per share   dolatrai vyas director    derivativenonderivative trans at  per share   anthony e maida director    derivativenonderivative trans at  per share   kurt a gustafson evp  chief financial officer    derivativenonderivative trans at  per share   joseph w turgeon president  coo    derivativenonderivative trans at  per share   rajesh c shrotriya chairman  ceo director    derivativenonderivative trans at  per share   joseph w turgeon president  coo    derivativenonderivative trans at  per share   kurt a gustafson evp  chief financial officer    derivativenonderivative trans at  per share   rajesh c shrotriya chairman  ceo director    award at  per share   joseph w turgeon president  coo    award at  per share   kurt a gustafson evp  chief financial officer    award at  per share   kurt a gustafson evp  chief financial officer    derivativenonderivative trans at  per share   rajesh c shrotriya chairman  ceo director    derivativenonderivative trans at  per share   joseph w turgeon president  coo    derivativenonderivative trans at  per share   kurt a gustafson evp  chief financial officer    derivativenonderivative trans at  per share   rajesh c shrotriya chairman  ceo director    derivativenonderivative trans at  per share   joseph w turgeon president  coo    derivativenonderivative trans at  per share   kurt a gustafson evp  chief financial officer    derivativenonderivative trans at  per share   rajesh c shrotriya chairman  ceo director    gift at  per share  newslatestcompanyussppi marketwatch news on sppi the best and worst smallcap stocks since donald trump’s election  pm jan    philip van doorn these smallcap stocks are expected to rise at least  in   am dec    philip van doorn spectrum pharmaceuticals stock drops after cancer treatment voted down by fda committee  pm sept    tomi kilgore spectrums qapzola didnt show substantial evidence of treatment effect over placebo fda committee says  pm sept    tomi kilgore spectrum pharmaceuticals qapzola cancer treatment gets thumbs down from fda panel  pm sept    tomi kilgore wall street expects these healthcare stocks to rise up to   pm may    philip van doorn wall street’s favorite stocks fly below the radar  am may    philip van doorn gopro gilead sciences celgene gain  pm dec    marketwatch spectrum submits bloodcancer drug for fda approval  am dec    chelsey dulaney these eight healthcare stocks could rise up to   pm aug    philip van doorn spectrum pharmaceuticals granted accelerated approval of lymphoma treatment  am july    tomi kilgore is biotech caught in a bubble and is it popping  pm april    russ britt three biopharma companies poised for product oks in  analyst  pm jan    russ britt onyx share surge lifts several boats in biotech harbor including etfs  am july    russ britt ligand lifts  outlook signs a license deal  am march    marketwatchcom stocks gain dow has longest win streak since   pm march    kate gibson spectrum pharma velti shares tumble after hours  pm march    carla mozee updates advisories and surprises  pm aug    marketwatch spectrum drops  after earnings report  am aug    val brickates kennedy stocks to watch thursday dupont great wolf  am april    marketwatch loading more headlines newsnonmarketwatchcompanyussppi other news on sppi arbutus seeks to eradicate hep b  am today am july    seeking alpha roches oryzon farewell spells more bad news for epigenetics  pm july    seeking alpha spectrum pharmaceuticals will rolontis substantially increase prospects  am july    seeking alpha spectrum pharmas folotyn and celgenes istodax combo shows treatment effect in treatmentresistant peripheral tcell lymphoma in earlystage study  am june    seeking alpha spectrum pharmaceuticals sppi bank of america merrill lynch  health care conference  slideshow  pm may    seeking alpha goodhaven funds firstquarter shareholder letter  am may    gurufocuscom ligand pharmaceuticals lgnd q earnings miss estimates  am may    zackscom q spectrum pharmaceuticals inc  am may    edgar online  edg  q k why spectrum pharmaceuticals stock is sinking today  pm may    motley fool spectrum pharmaceuticals sppi ceo rajesh shrotriya on q  results  earnings call transcript  pm may    seeking alpha spectrum pharmaceuticals  off q earnings miss  pm may    seeking alpha epizyme why is big pharma interested in this small biotech  pm may    seeking alpha notable earnings after tuesday’s close  pm may    seeking alpha spectrum sppi initiates phase ii study for cancer candidate  am march    zackscom midstage study launched assessing spectrum pharmas poziotinib in certain lung cancer patients  am march    seeking alpha k spectrum pharmaceuticals inc  pm march    edgar online  edg  q k spectrum sppi q loss narrower than expected sales beat  am march    zackscom spectrum pharmaceuticals sppi ceo rajesh shrotriya on q  results  earnings call transcript  pm march    seeking alpha spectrum pharma q top line down  net loss widens shares down  after hours  pm march    seeking alpha whats in store for maxpoint mxpt this earnings season  am march    zackscom loading more headlines at a glance spectrum pharmaceuticals inc  south eastern avenue suite  henderson nevada  phone   industry pharmaceuticals sector health carelife sciences fiscal yearend  view sec filings revenue m net income m employees  annual report for sppi newspressreleasecompanyussppi press releases on sppi spectrum pharmaceuticals announces second quarter  financial results teleconference and webcast  am july    businesswire  bzx spectrum pharmaceuticals highlights three abstracts of clinical data at the  american society of clinical oncology asco annual meeting in chicago illinois june    am june    businesswire  bzx spectrum pharmaceuticals to present corporate update at the jefferies  global healthcare conference on june th  am may    businesswire  bzx spectrum pharmaceuticals to present corporate update at the bank of america merrill lynch  health care conference on may   am may    businesswire  bzx spectrum pharmaceuticals to present corporate update at the nd annual deutsche bank health care conference on may   am april    businesswire  bzx spectrum pharmaceuticals announces first quarter  financial results teleconference and webcast  am april    businesswire  bzx todays research reports on biotech stocks to watch celldex therapeutics and spectrum pharmaceuticals  am april    accesswire research reports initiation on biotech stocks  la jolla pharma spectrum pharma advaxis and aevi genomic  am april    pr newswire  prf spectrum pharmaceuticals highlights three abstracts on rolontis™ eflapegrastim and beleodaq® belinostat for injection at the american association for cancer research aacr annual meeting in washington dc april    am march    businesswire  bzx spectrum pharmaceuticals announces fourth quarter and full year  financial results teleconference and webcast  am march    businesswire  bzx spectrum pharmaceuticals partnering deals and alliances  to   pm feb    pr newswire  prf spectrum pharmaceuticals to present corporate update at the  rbc capital markets global healthcare conference on february rd  am feb    businesswire  bzx research reports coverage on biotech stocks  anavex life sciences omeros spectrum pharma and lexicon pharma  am feb    pr newswire  prf research reports initiation on biotech stocks  incyte anavex life sciences portola pharma and spectrum pharma  am dec    pr newswire  prf spectrum pharmaceuticals highlights survival advantage in a case match control analysis of the propel study with folotyn® pralatrexate injection at the th annual meeting of the american society of hematology ash  am dec    businesswire  bzx spectrum pharmaceuticals highlights five abstracts on rolontis™ eflapegrastim and poziotinib at the san antonio breast cancer symposium sabcs in san antonio texas december    am dec    businesswire  bzx casi pharmaceuticals import drug registration application for evomela® accepted for review by cfda  am dec    pr newswire  prf spectrum pharmaceuticals highlights four abstracts at the th annual meeting of the american society of hematology ash in san diego california december    am dec    businesswire  bzx shareholder alert purcell julie  lefkowitz llp is investigating spectrum pharmaceuticals inc for potential breaches of fiduciary duty by its board of directors  pm nov    accesswire day deadline khang  khang llp announces securities class action lawsuit against spectrum pharmaceuticals inc and encourages investors with losses to contact the firm  pm nov    accesswire loading more headlines trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york open marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest pwhy mccain shot down obamacare repeal pchip stocks are cool again but reality is here pintel earnings have message for amd and nvidia ‘bring it on’ pamazon’s freespending ways hit earnings but don’t expect a shift to thrift pstarbucks’ teavana stores are the latest casualty at the mall pwagerebound story takes another hit after drab eci report pwhat is an ico ptrump’s sketch of new york city skyline auctioned off pwells fargo fda plan to lower nicotine could be opportunity for altria philip morris phealthcare fund managers say a spike in drugs and devices will produce big returns pthese companies spent over  billion buying back shares while their ceos were dumping them pstock market edges lower on track for weekly losses awells fargo will pay  million to overcharged auto loan consumers agold aims for thirdweekly gain as dollar holds loss after gdp report acharting a bulltrend whipsaw nasdaq’s key reversal fuels sector rotation again aa global investment strategist offers up a summer reading list to make you a better investor athis fund strategist says there’s at least one way companies can survive amazon’s onslaught awells fargo fda plan to lower nicotine could be opportunity for altria philip morris ahere’s one trump fan who might make you some money awhat the solar eclipse on aug  will mean for stocks loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  bing places for business bing places for business sign in using your microsoft account work account google account facebook account dont have an account create one spectrum pharmaceuticals inc a global commercialstage biotechnology company our company our company company philosophy partnerships management board of directors careers product portfolio product portfolio commercial latestage rolontistm eflapegrastim qapzolatm apaziquone development poziotinib outlicensing glossary product returns investor relations investor relations press releases events and presentations corporate governance management board of directors committee composition insider transactions annual report and proxy information financial information sec filings k annual reports quarterly results financial statements stock information historic stock lookup investment calculator stocksplit history analyst coverage ownership profile investor faqs patient assistance medical professionals medical professionals clinical trials grants investigator initiated trials expanded access program careers contact us our commitment to patients spectrums core mission is to bring pharmaceutical products to patients for unmet medical needs to this mission we bring our years of drug development expertise coupled with the insight of working in many different oncology indications learn more  our products spectrum and its subsidiaries have six marketed oncologyhematology products three for different types of nonhodgkins lymphoma one for advanced metastatic colorectal cancer one for a certain type of acute lymphoblastic leukemia all and one for multiple myeloma there are two products in latestage development as well as a broad and diversified portfolio of proprietary drugs in various stages of development all with a focus on oncology and hematology learn more  company highlights spectrum pharmaceuticals announces second quarter  financial results teleconference and webcastthursday july   spectrum pharmaceuticals highlights results of a combination study of folotynž pralatrexate injection plus romidepsin presented at the th international conference on malignant lymphoma icml meetingmonday june th  spectrum pharmaceuticals highlights three abstracts of clinical data at the  american society of clinical oncology asco annual meeting in chicago illinois june  friday june nd  expanding patient options our passion to deliver additional options for patients suffering from cancer is behind every action we take we will work to understand their needs and develop new and innovative therapies that offer hope for improved disease outcomes learn more about the spectrum philosophy our company company philosophy partnerships management board of directors careers product portfolio commercial latestagedevelopment glossary product returns investor relations press releases events and presentations corporate governance annual report and proxy information financial information stock information investor faqs patient assistance star medical professionals clinical trials medical affairs grants investigator initiated trials careers contact us this web site contains forwardlooking statements within the meaning of section a of the securities act of  as amended and section e of the securities exchange act of  as amended and in reliance upon the safe harbor provisions of the private securities litigation reform act of  such forwardlooking statements are based on the beliefs of the companys management as well as assumptions made by and information currently available to the companys management readers should not put undue reliance on these forwardlooking statements forwardlooking statements are inherently subject to risks and uncertainties some of which cannot be predicted or quantified spectrum pharmaceuticals incs actual results may differ materially from the results projected in the forwardlooking statements factors that might cause such a difference include but are not limited to those discussed in the companys most recent form k and qs we do not plan to update any such forwardlooking statements and expressly disclaim any duty to update the information contained in this filing except as required by law all contents copyright spectrum pharmaceuticals inc š  all rights reserved ppall site map  privacy policy  terms of use  linking policy  contact us remote support  clinical support  webmail spectrum pharmaceuticals inc  product pipeline review   infowiseguyreportscom     chat with us           us         uk login register home report categories premium reports access to  premium reports aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports report categories aerospace  defense agri  food automotive basic materials consumer goods  retail energy life sciences manufacturing  construction services telecom  it education security  intelligence systems technology company reports publisher knowledgestore countries browse by country browse by continent browse by group  region conferences upcoming conferences seminars conferences upcoming conferences seminars countries browse by country browse by continent browse by group  region news  blog press release blog news  blogs press release blogs faqs about us about our company our team life at wgr careers contact us there are no items currently in your basket there are no items currently in your basket search home all reports spectrum pharmaceuticals inc  product pipeline review  spectrum pharmaceuticals inc  product pipeline review   wgr  april  global  pages global markets direct description table of content sample report enquiry before buy related reports spectrum pharmaceuticals inc  product pipeline review  summaryglobal markets direct’s ‘spectrum pharmaceuticals inc  product pipeline review  ’ provides an overview of the spectrum pharmaceuticals inc’s pharmaceutical research and development focusthis report provides comprehensive information on the current therapeutic developmental pipeline of spectrum pharmaceuticals inc’s complete with comparative analysis at various stages therapeutics assessment by drug target mechanism of action moa route of administration roa and molecule type it also reviews latest updates and featured news and press releases along with special features on latestage and discontinued projectsglobal markets direct’s report features investigational drugs from across globe covering over  therapy areas and nearly  indications the report is built using data and information sourced from global markets direct’s proprietary databases companyuniversity websites sec filings investor presentations and featured press releases from companyuniversity sites and industryspecific third party sources put together by global markets direct’s team drug profilesrecords featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information additionally processes including live news  deals tracking browser based alertbox and clinical trials registries tracking ensure that the most recent developments are captured on a real time basisthe report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage it strengthens rd pipelines by identifying new targets and moas to produce firstinclass and bestinclass productsnote certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated diseasescope the report provides brief overview of spectrum pharmaceuticals inc including business description key information and facts and its locations and subsidiaries the report reviews current pipeline of spectrum pharmaceuticals inc’s human therapeutic division and enlists all their major and minor projects the report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones  special feature on outlicensed and partnered product portfolio the report summarizes all the dormant and discontinued pipeline projects latest company statement  latest news and deals relating to the spectrum pharmaceuticals inc’s pipeline productsreasons to buy evaluate spectrum pharmaceuticals inc’s strategic position with total access to detailed information on its product pipeline assess the growth potential of spectrum pharmaceuticals inc in its therapy areas of focus identify new drug targets and therapeutic classes in the spectrum pharmaceuticals inc’s rd portfolio and develop key strategic initiatives to reinforce pipeline in those areas exploit inlicensing opportunities by identifying windows of opportunity to fill portfolio gaps develop strategic initiatives by understanding the focus areas of spectrum pharmaceuticals inc and exploit collaboration and partnership opportunities identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage plan mergers and acquisitions effectively by identifying the most promising pipeline of spectrum pharmaceuticals inc develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope explore the dormant and discontinued projects of spectrum pharmaceuticals inc and identify potential opportunities in those areas avoid intellectual property rights related issues table of contentstable of contents list of tables list of figures spectrum pharmaceuticals inc snapshot spectrum pharmaceuticals inc overview key information key facts spectrum pharmaceuticals inc  research and development overview key therapeutic areas spectrum pharmaceuticals inc  pipeline review pipeline products by stage of development pipeline products  monotherapy pipeline products  partnered products partnered productscombination treatment modalities spectrum pharmaceuticals inc  pipeline products glance spectrum pharmaceuticals inc  late stage pipeline products preregistration productscombination treatment modalities phase iii productscombination treatment modalities spectrum pharmaceuticals inc  clinical stage pipeline products phase ii productscombination treatment modalities phase i productscombination treatment modalities spectrum pharmaceuticals inc  early stage pipeline products preclinical productscombination treatment modalities spectrum pharmaceuticals inc  unknown stage pipeline products unknown productscombination treatment modalities spectrum pharmaceuticals inc  drug profiles melphalan product description mechanism of action rd progress apaziquone product description mechanism of action rd progress pralatrexate product description mechanism of action rd progress vincristine sulfate product description mechanism of action rd progress yttritum  ibritumomab tiuxetan product description mechanism of action rd progress belinostat product description mechanism of action rd progress lucanthone hydrochloride product description mechanism of action rd progress menadione product description mechanism of action rd progress ortataxel product description mechanism of action rd progress ozarelix product description mechanism of action rd progress spi product description mechanism of action rd progress spi product description mechanism of action rd progress mtrn product description mechanism of action rd progress spi product description mechanism of action rd progress topotecan hydrochloride liposomal product description mechanism of action rd progress vinorelbine tartrate liposomal product description mechanism of action rd progress rituximab biosimilar product description mechanism of action rd progress spectrum pharmaceuticals inc  pipeline analysis spectrum pharmaceuticals inc  pipeline products by target spectrum pharmaceuticals inc  pipeline products by route of administration spectrum pharmaceuticals inc  pipeline products by molecule type spectrum pharmaceuticals inc  pipeline products by mechanism of action spectrum pharmaceuticals inc  recent pipeline updates spectrum pharmaceuticals inc  dormant projects spectrum pharmaceuticals inc  discontinued pipeline products discontinued pipeline product profiles efaproxiral ortataxel rh spectrum pharmaceuticals inc  company statement spectrum pharmaceuticals inc  locations and subsidiaries head office other locations  subsidiaries appendix methodology coverage secondary research primary research expert panel validation contact us disclaimer list of tablesspectrum pharmaceuticals inc key information spectrum pharmaceuticals inc key facts spectrum pharmaceuticals inc  pipeline by indication  spectrum pharmaceuticals inc  pipeline by stage of development  spectrum pharmaceuticals inc  monotherapy products in pipeline  spectrum pharmaceuticals inc  partnered products in pipeline  spectrum pharmaceuticals inc  partnered products combination treatment modalities  spectrum pharmaceuticals inc  preregistration  spectrum pharmaceuticals inc  phase iii  spectrum pharmaceuticals inc  phase ii  spectrum pharmaceuticals inc  phase i  spectrum pharmaceuticals inc  preclinical  spectrum pharmaceuticals inc  unknown  spectrum pharmaceuticals inc  pipeline by target  spectrum pharmaceuticals inc  pipeline by route of administration  spectrum pharmaceuticals inc  pipeline by molecule type  spectrum pharmaceuticals inc  pipeline products by mechanism of action  spectrum pharmaceuticals inc  recent pipeline updates  spectrum pharmaceuticals inc  dormant developmental projects spectrum pharmaceuticals inc  discontinued pipeline products  spectrum pharmaceuticals inc other locations spectrum pharmaceuticals inc subsidiaries list of figuresspectrum pharmaceuticals inc  pipeline by top  indication  spectrum pharmaceuticals inc  pipeline by stage of development  spectrum pharmaceuticals inc  monotherapy products in pipeline  spectrum pharmaceuticals inc  partnered products in pipeline  spectrum pharmaceuticals inc  pipeline by top  target  spectrum pharmaceuticals inc  pipeline by top  route of administration  spectrum pharmaceuticals inc  pipeline by top  molecule type  spectrum pharmaceuticals inc  pipeline products by top  mechanism of action   request a sample report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro do you have any specific field of interest confirm make an enquiry before buying this report name email optional request you to please fill in your corporate emailid job title company phone no your country select country afghanistan albania algeria american samoa andorra angola anguilla antigua  barbuda argentina armenia aruba australia austria azerbaijan bahamas bahrain bangladesh barbados belarus belgium belize benin bermuda bhutan bolivia bosnia  herzegovina botswana brazil brunei bulgaria burkina faso burundi cambodja cameroon canada cape verde cayman islands central african republic chad chile china colombia comoros congobrazzaville congokinshasa cook islands costa rica cote divoire croatia cuba cyprus czech republic denmark djibouti dominica dominican republic ecuador egypt el salvador equatorial guinea eritrea estonia ethiopia falkland malvinas faroes fiji finland france frenchguiana tahitifrench polinesia gabon gambia georgia germany ghana gibraltar greece greenland grenada guadeloupe guam guatemala guinea guineabissau guyana haiti vatican city honduras hong kong hungary iceland india indonesia iran iraq ireland israel italy jamaica japan jordan kazakhstan kenya kiribati north korea south korea kuwait kyrgyzstan laos latvia lebanon lesotho liberia libya liechtenstein lithuania luxembourg macao macedonia madagascar malawi malaysia maldives mali malta marshall islands martinique mauritania mauritius mexico micronesia moldova monaco mongolia montserrat morocco mozambique myanmar namibia nauru nepal netherlands netherlands antilles new caledonia new zealand nicaragua niger nigeria norfolk northern mariana norway oman pakistan palau panama papua new guinea paraguay peru philippines pitcairn poland portugal puerto rico qatar reunion romania russian federation rwanda saint helena saint lucia saint pierre and miquelon st vincent  the grenadines samoa san marino sao tome  principe saudi arabia senegal seychelles sierra leone singapore slovakia slovenia solomon islands somalia south africa spain sri lanka sudan suriname svalbard and jan mayen swaziland sweden switzerland syria taiwan tajikistan tanzania thailand togo tokelau tonga trinidad  tobago tunisia turkey turkmenistan turks and caicos islands tuvalu uganda ukraine united arab emirates united kingdom united states of america uruguay uzbekistan vanuatu venezuela viet nam virgin islands british virgin islands us wales western sahara yemen zambia zimbabwe timorleste curacao st kitts  nevis sint maarten guernsey isle of man jersey niue montenegro your enquiry confirm purchase this market research report usd gbp euro yen inr user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  user pdf  site pdf  enterprise pdf  add to cart buy now   email report   sample report   save page   any questions   download information   check discount   download order form   email report   sample report   save page   any questions   download information   check discount   download order form contact us akash anand domain head business development saleswiseguyreportscom     us     uk rishabh arora domain head business development saleswiseguyreportscom  abu koshy domain head business development saleswiseguyreportscom     related reports × tell a friend about this report your name your email friends name friends email your enquiry send